AAA announces Ph3 NETTER-2 study with Lutathera as 1st Line in advanced GEP-NET
Credit: Advanced Accelerator Applications Saint-Genis-Pouilly, France, March 25, 2020 - Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced that the first patient has...
















